The Marketbuzz Podcast: GIFT Nifty points to a gap-down; Dabur gets a downgrade
Marketbuzz Podcast: Indian markets may see a gap-down start according to the GIFT Nifty. Watch out for stocks like Angel One, BSE, Bharat Forge and others.
Uncategorized
Japanese stocks rise as Prime Minister’s comments weaken yen
The yen tumbled about 2% against the dollar Wednesday, its worst day since June 2022, after Shigeru Ishiba said the economy isn’t ready for another hike.
Stock Market LIVE Updates: Indian indices to resume trading after holiday, Wall Street sees marginal gains amid escalating geopolitical tensions
Stock Market LIVE Updates: On Tuesday, Nifty traded within a 160-point range but ended slightly below the flat line, marking its third consecutive day of losses. The early weekly expiry of Nifty Bank and the financial services expiry contributed to…
US markets remain on the edge as middle east tensions rise, payroll data looms
Treasuries slid and the US dollar climbed after stronger-than-expected jobs numbers dampened Wall Street’s confidence that the Federal Reserve’s next interest-rate cut would be a big one.
Levi shares fall 10% in extended trading after paring guidance
Sales in the fiscal third quarter, which ended August 25, were slightly short of the average analyst estimate, while Levi’s Americas division posted a revenue decline in the period.
Dr. Reddy’s inks licensing pact with Gilead to commercialise HIV drug
Lenacapavir is a US Food and Drug Administration (FDA) approved medication indicated for the treatment of HIV type 1 (HIV-1) infection in heavily treatment-experienced adults facing multi-drug resistant HIV-1. The Dr. Reddy’s stock price settled at ₹6,750.85 on the NSE…
Anil Ambani’s Reliance Group forays into Bhutan, to set up 1,270 MW projects
The partnership will prioritise green energy generation, focusing on solar and hydropower initiatives while also exploring innovative green technologies.
China’s property market faces challenges despite stimulus, experts say
Ed Yardeni, President of Yardeni Research, expressed doubts about the effectiveness of China’s efforts to revive its struggling real estate market.
Trade Setup for October 3: 25,750 key for Nifty as geopolitical tensions rise ahead of weekly expiry
Thursday will also be the weekly options expiry of the Nifty contracts and business updates for companies will continue as usual.
Zydus Lifesciences gets USFDA nod to produce prostrate cancer drug
Zydus Lifesciences has received tentative approval from the US Food and Drug Administration (USFDA) to manufacture Enzalutamide tablets (40 mg and 80 mg), the drug maker said in a regulatory filing.